Morgan Stanley Maintains Overweight on CVS Health, Raises Price Target to $111

Benzinga Newsdesk www.benzinga.com Positive 78.7%

Neg 0% Neu 0% Pos 78.7%

Morgan Stanley analyst Erin Wright maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $106 to $111.